Pipeline

Cartherics has an extensive and growing patent portfolio, complemented by agreements providing access to key third party technology for gene edited immunotherapies.

The initial target cancers for Cartherics’ immune stem cell products are adenocarcinomas and, in particular, ovarian cancer. The target indications will be expanded to gastric, pancreatic, prostate, small cell lung cancer and triple negative breast cancer as Cartherics advances its development program.